Form 8-K: Item 5.02 Departure of Directors or Certain Officers

BPTH_20250624_8-K

Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

BPTH_Life_Sciences_Virtual_Investor_Forum_Announcement

Bio-Path Holdings Provides Clinical and Operational Update

BPTH_Clinical_Program_Update_June_2025

Webcast link to Corporate Update Conference Call on Thursday, May 29, 2025 at 8:30 a.m. ET

Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

BPTH_Corporate_Update_Conference_Call_Announcement_20250522

SEC Form 1-A/A

BPTH_1-A-A_20250516

SEC Form 10-Q: For Period ending March 31, 2025

BPTH_20250515_10-Q

SEC Form 8-K: Press Release dated May 1, 2025

BPTH_8-K_20250502

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

BP1001-A_Obesity_Third_Efficacy_Milestone

SEC Form 8-K: Entry into a Material Definitive Agreement

BPTH_8-K_20250429